RESUMO
This study was performed in 97 hemodialysis patients (85 on HD and 12 on CAPD) to investigate the possible correlation between B2-m and hemodialysis-related amyloidosis syndromes (HRA-S); differences in B2-m and HRA behavior between patients hemodialysed with cellulose and synthetic membranes were also included in the present study. Data indicate that B2-m levels are not correlated with dialysis length or with the type of membrane used for the dialysis. On the contrary, in 16 patients with the Carpal Tunnel Syndrome, a significant correlation was found between the CTS, the dialysis length and the type of membrane (greater incidence with cellulosic membranes).
Assuntos
Amiloidose/etiologia , Diálise Peritoneal Ambulatorial Contínua/efeitos adversos , Diálise Renal/efeitos adversos , Uremia/sangue , Microglobulina beta-2/metabolismo , Adulto , Idoso , Amiloidose/sangue , Proteínas Sanguíneas/metabolismo , Síndrome do Túnel Carpal/sangue , Síndrome do Túnel Carpal/etiologia , Celulose/química , Estudos de Coortes , Feminino , Humanos , Masculino , Membranas Artificiais , Pessoa de Meia-Idade , Uremia/terapiaRESUMO
From 1986 to 91, 174 dialysis patients were studied. The prevalence of previous HBV infection and of chronic carriers was 33.3 and 4.6%, respectively. Immunization rate after vaccination (3 doses) was 63%. In 1991, we proposed a vaccination with 4 doses and recommend a 6-monthly anti-HBs evaluation to assess the timing of any booster dose needed.
Assuntos
Hepatite B/transmissão , Diálise Renal/efeitos adversos , Idoso , Portador Sadio/prevenção & controle , Infecção Hospitalar/prevenção & controle , Infecção Hospitalar/transmissão , Feminino , Hepatite B/prevenção & controle , Anticorpos Anti-Hepatite B/sangue , Vacinas contra Hepatite B , Vírus da Hepatite B/imunologia , Hepatite Crônica/prevenção & controle , Humanos , Masculino , Pessoa de Meia-Idade , Vacinas contra Hepatite Viral/uso terapêuticoRESUMO
Because of the great problem of viral hepatitis in hemodialysis patients, the Italian Society of Nephrology decided to perform a national epidemiologic survey. We contacted 467 nephrological centers by a questionnaire which let us have information on 25,746 uremic patients: 18,338 on HD, 2,250 on PD and 5,176 with kidney transplant, respectively 78.5% of the total Italian dialysed patients and 91.4% of the total transplanted patients. Statistical analyses were performed. HBV infections occur in 7.8% of the patients (2,008 cases) but considering that 485 cases became spontaneously negative, the true overall incidence of chronic carriers falls to 4.9%. The main causes of the infection are reported as transfusions (64.3%) and dialysis environment (12%). The vaccination program performed by 93.2% of the centers, obtained an efficacious seroconversion in 4,626 of 7,790 cases vaccinated: the vaccine currently most utilized is the recombinant type administered by means of 3 versus 4 boosters. In the 2nd part of the survey, we report information concerning the presence of nephropaties associated with HBV infections in nonuremic patients (208 cases). We present and discuss the clinical picture of the nephropaties, the hystologic bioptic pattern and the prognosis of the kidney pathology.
Assuntos
Hepatite B/epidemiologia , Diálise Renal/efeitos adversos , Portador Sadio/epidemiologia , Infecção Hospitalar/epidemiologia , Infecção Hospitalar/prevenção & controle , Coleta de Dados , Hepatite B/prevenção & controle , Hepatite B/transmissão , Vacinas contra Hepatite B , Humanos , Itália/epidemiologia , Transplante de Rim/efeitos adversos , Diálise Peritoneal/efeitos adversos , Vacinas contra Hepatite Viral/uso terapêuticoRESUMO
In our Dialytic Unit, the prevalence of antibodies to HCV (anti-HCV) was 16.4% in 1990 (73 hemodialyzed) and 21% in 1991 (105 hemodialyzed). The incidence of seroconversion was 13.1%. The transaminase behavior was similar in a group of anti-HCV-positive and a group of anti-HCV-negative patients and with previous HBV infection. Blood transfusions and dialytic age did not affect anti-HCV positivity.